<DOC>
	<DOC>NCT01457352</DOC>
	<brief_summary>The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.</brief_summary>
	<brief_title>Efficacy and Safety of SPARC0921 in Subjects With Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Men and women age 18 years and older Known history of spasticity due to MS prior to starting baclofen Able and willing to comply with the protocol, including availability for a scheduled clinic visits Willingness and giving of written informed consent In relapse or history of unstable course over the prior 30 days prior to the Screening Visit Concomitant neurologic conditions causing spasticity Has received an investigational drug or device within 30 days that would interfere with the study goals prior to the Screening Visit Unable to comply with study procedures in the opinion of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Baclofen, spasticity</keyword>
</DOC>